Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy

Table 3 Bivariate analysis of background factors associated with frequency scale for symptoms of gastroesophageal reflux disease scores in the non-erosive reflux disease patients

Background factors	FSSG scores of the applicable subjects for the factor [mean ± SD (the number)]	FSSG scores of the inapplicable subjects for the factor [mean ± SD (the number)]	P value
Gender (male)	6.5 ± 5.2 (8)	11.3 ± 6.2 (12)	0.0807
Atrophic gastritis	9.6 ± 6.7 (13)	9.0 ± 5.4 (7)	0.9365
Hiatal hernia	7.1 ± 5.0 (12)	12.9 ± 6.4 (8)	0.1510
Alcohol consumption habit	9.0 ± 6.8 (6)	10.2 ± 6.4 (12)	0.4221
Smoking habit	6.0 (1)	10.0 ± 6.5 (17)	0.6270
Use of half dose of PPI	7.2 ± 5.7 (6)	10.4 ± 6.3 (14)	0.2454
Use of rabeprazole	11.8 ± 7.0 (10)	7.0 ± 4.3 (10)	0.2095
Concomitant drug against GERD	10.5 ± 6.7 (6)	8.9 ± 6.1 (14)	0.5896
Use of Ca antagonist	9.0 ± 6.2 (9)	9.7 ± 6.4 (11)	0.5159
Use of ASA	9.6 ± 6.0 (5)	9.3 ± 6.4 (15)	0.8262
Use of NSAIDs	18.0 (1)	8.9 ± 6.0 (19)	0.2568
CYP2C19 RM genotype	5.5 ± 1.0 (6)	11.8 ± 6.3 (13)	0.0151
Age	ρ = 0.0963		0.6863
BMI	ρ = -0.3714		0.1069

FSSG: Frequency scale for symptoms of gastroesophageal reflux disease; NERD: Non-erosive reflux disease; PPI: Proton pump inhibitor; ASA: Acetylsalicylic Acid; NSAIDs: Non-steroidal anti-inflammatory drugs; CYP2C19: Cytochrome P450 2C19; RM: Rapid metabolizer; IM: Intermediate metabolizer; PM: Poor metabolizer; BMI: Body mass index.